We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sirnaomics announced dose administration for the first patient in a Phase 2a clinical study of the company's lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma.
Sirnaomics announced the U.S. Food and Drug Administration (FDA) has agreed to the company's proposed trial design for a Phase 2 clinical study to .....